---
schema_version: "secwatch.filing_event.v1"
accession: "0001070081-23-000048"
form_type: "8-K"
ticker: "PTCT"
cik: "0001070081"
company_name: "PTC THERAPEUTICS, INC."
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T07:07:09.377484+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# PTC Therapeutics Q2 revenue $214M (+29% YoY); raises full-year guidance to $940M-$1.0B

## Summary
- Total revenue $213.8M vs $165.5M Q2 2022; DMD franchise $162M (+21%).
- Translarna net revenue $96.5M; Emflaza $65.7M; Evrysdi royalties $36.9M.
- Sepiapterin APHENITY trial met primary endpoint; NDA filing planned Q4 2023.
- GAAP net loss $198.9M; cash $337.9M; gene therapy discontinues caused $88M non-cash charge.
- Full-year 2023 total revenue guidance raised to $940M-$1.0B; DMD product revenue guidance $545-$575M.

## SEC filing metadata
- accession: 0001070081-23-000048
- form_type: 8-K
- ticker: PTCT
- cik: 0001070081
- company_name: PTC THERAPEUTICS, INC.
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070081/000107008123000048/0001070081-23-000048-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070081/000107008123000048/tmb-20230803x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001070081-23-000048
- JSON: https://secwatch.observer/filing/0001070081-23-000048.json
- Plain text: https://secwatch.observer/filing/0001070081-23-000048.txt

## Key facts
- Earnings Releases
  PTC THERAPEUTICS, INC. reported financial results for the second quarter ending June 30, 2023.
  - Period: the second quarter ending June 30, 2023
  - Result: reported results
  source text: On August 3, 2023, PTC Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1070081/000107008123000048/0001070081-23-000048-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.